secondary prevention in patients with acs and diabetes: how can we optimize therapy?
DESCRIPTION
Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?. Panelists. Learning Objectives. Learning Objectives. Diabetes as a CV Risk Factor. Impact of Gluco-Metabolic Characteristics on Risk of Major Cardiovascular Events. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/1.jpg)
Secondary Prevention in Patients With ACS and Diabetes:
How Can We Optimize Therapy?
![Page 2: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/2.jpg)
Panelists
![Page 3: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/3.jpg)
Learning Objectives
![Page 4: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/4.jpg)
Learning Objectives
![Page 5: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/5.jpg)
Diabetes as a CV Risk Factor
![Page 6: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/6.jpg)
Impact of Gluco-Metabolic Characteristics on Risk of Major
Cardiovascular Events
![Page 7: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/7.jpg)
![Page 8: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/8.jpg)
![Page 9: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/9.jpg)
Risk Factors in Patients With T2D After ACS
![Page 10: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/10.jpg)
The HDL Hypothesis
![Page 11: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/11.jpg)
Meta-analysis of Intensive Statin Trials:
Coronary Death or Myocardial Infarction
![Page 12: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/12.jpg)
Intensive Glucose Control in Critically Ill Patients: Death From
Any Cause
![Page 13: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/13.jpg)
![Page 14: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/14.jpg)
UKPDS: Extended Follow-up Benefits of Glycemic Control
![Page 15: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/15.jpg)
![Page 16: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/16.jpg)
Comparison of CETP Inhibitors
![Page 17: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/17.jpg)
DAL-OUTCOMES: 3 Years
![Page 18: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/18.jpg)
AIM-HIGH: End Point at 36-month Follow-up
![Page 19: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/19.jpg)
ACCORD Lipid: Hazard Ratios for the Primary Outcome
![Page 20: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/20.jpg)
SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in
T2D
![Page 21: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/21.jpg)
AleCardio: Aleglitazar in Patients With T2D and ACS
![Page 22: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/22.jpg)
Unmet Needs: Diabetes in Post-ACS Patients
![Page 23: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/23.jpg)
Abbreviations
![Page 24: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/24.jpg)
Abbreviations (cont)
![Page 25: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/25.jpg)
Abbreviations (cont)
![Page 26: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/26.jpg)
References
![Page 27: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/27.jpg)
References (cont)
![Page 28: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/28.jpg)
References (cont)
![Page 29: Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?](https://reader036.vdocuments.site/reader036/viewer/2022081604/56815df3550346895dcc2666/html5/thumbnails/29.jpg)
References (cont)